DUBLIN, Ireland , Dec. 11, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, today ...
Advocacy and Industry Form Nocturia Council to Sound the Alarm That Waking Up Multiple Times at Night to Urinate, a Treatable Medical Condition Called Nocturia, Is Causing Distressing Health Issues WASHINGTON , Nov. 29, 2018 ...
We are a global pharmaceutical company, proud to be unique in our space as experts in the development and commercialization of safe, novel products that address unmet medical needs through improved dosing and by ensuring the safety and efficacy of our products and product candidates.
Whether we are seeking FDA approval of commonly used drugs, acquiring new assets or utilizing our innovative technologies to change the method of administering medication, Avadel approaches every product with the patient in mind.